SGC Frankfurt


The Structural Genomics Consortium at the Goethe University Frankfurt (SGC Frankfurt) is a research node of the SGC, an international public private partnership and open science network. The SGC catalyses new research areas of human biology by providing high resolution structure information, assay systems and chemical tools. The main focus of the SGC node in Frankfurt are protein kinases, proteins regulating the ubiquitin system as well as epigenetic mechanisms. The site coordinates the Innovative Medicine Initiative (IMI) Program EUbOPEN and it is a partner in the Target2035 initiative, two large international efforts with the goal covering the human proteome with high quality chemical tools.





May 2021

Open position: Junior Group Leader in Translation Cancer Research with focus on Drug Target Validation in Preclinical Cancer Models. Read more


March 2021

Do you want to develop web-based tools to support a global effort on translational medicine and open science? - We are looking for a skilled, highly motivated and experienced full-stack web developer to support an international open science effort in translational medical research. The position is open in Stockholm, Frankfurt or Toronto. This is an exciting opportunity to work with diverse high-quality data types to develop novel web-based tools and platforms for data capture and dissemination. We offer a multi-national and collaborative research environment with partners in academia and the biomedical industry worldwide. Read more


June 2020

New consortium EUbOPEN will provide tools to unlock disease biology – Congratulation to Stefan Knapp and colleagues from the Goethe University, who just received a prestigious IMI grant for a large-scale effort for the development of an open access chemogenomic compound libraries and chemical probes. The newly formed public-private partnership “Enabling and Unlocking biology in the OPEN” (EUbOPEN) was launched on 1 May 2020, with a total budget of 65.8 million euros covered by a grant from the Innovative Medicines Initiative (IMI) and cash/in-kind contributions from EFPIA companies and IMI Associated Partners and contributions from partners outside of Europe.



Berger BT, Amaral M, Kokh DB, Nunes-Alves A, Musil D, Heinrich T, Schröder M, Neil R, Wang J, Navratilova I, Bomke J, Elkins JM, Müller S, Frech M, Wade RC, Knapp S. Structure-kinetic relationship reveals the mechanism of selectivity of FAK inhibitors over PYK2. Cell Chem Biol. 2021 Link


Malik AU, Karapetsas A, Nirujogi RS, Mathea S, Chatterjee D, Pal P, Lis P, Taylor M, Purlyte E, Gourlay R, Dorward M, Weidlich S, Toth R, Polinski NK, Knapp S, Tonelli F, Alessi DR. Deciphering the LRRK code: LRRK1 and LRRK2 phosphorylate distinct Rab proteins and are regulated by diverse mechanisms. Biochem J. 2021 Link


Deniston C K, Salogiannis J, Mathea S, Snead D M, Lahiri I, Matyszewski M, Donosa O, Watanabe R, Böhning J, Shiau A K, Knapp S, Villa E, Reck-Peterson S L, Leschziner A E. Structure of LRRK2 in Parkinson’s disease and model for microtubule interaction. Nature. 2020 Link




Susanne Müller-Knapp
Chief Operating Officer
Tel: +49 (0) 69 798-42501
contact (at)

Max-von-Laue-Straße 15,
60438 Frankfurt am Main



Funding acknowledgement

The Structural Genomics Consortium is a registered charity (no: 1097737) that receives funds from; AbbVie, Bayer AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genentech, Genome Canada through Ontario Genomics Institute [OGI-196], EU/EFPIA/OICR/McGill/KTH, Diamond Innovative Medicines Initiative 2 Joint Undertaking [EUbOPEN grant 875510], Janssen, Merck KGaA (aka EMD in Canada and US), Merck & Co (aka MSD outside Canada and US), Pfizer, São Paulo Research Foundation-FAPESP, Takeda and Wellcome [106169/ZZ14/Z].